GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival

Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures

Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology